| Stage III melanoma patients are a heterogeneous population and biomarkers for disease recurrence have not been established to date. |
| Biomarkers for a strong adaptive immune response seem to identify patients who derive clinical benefit from adjuvant therapy. |
| Results in a neoadjuvant setting need to be implemented and prospectively confirmed to be employed in everyday clinical practice. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.